Global Intravenous Immunoglobulin (IVIG) Market is Expected to Reach $11.6 Billion, by 2021 - Allied Market Research

PORTLAND, Oregon, April 16, 2015 /PRNewswire/ --

A new report by Allied Market Research, titled, "Global Intravenous Immunoglobulin (IVIG) Market - Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2014-2021", forecasts the Intravenous immunoglobulin (IVIG) market to grow at a CAGR of 6.8% between 2015 and 2021. Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), immunodeficiency are the most prominent disease classes, collectively contributing about 53% of the global IVIG market revenue in 2014. Myasthenia Gravis would be the fastest growing segment with a double digit growth during the forecast period, due to the increasing adoption of IVIG as first line treatment.

     (Logo: http://photos.prnewswire.com/prnh/20140911/647229)

To view the report, visit the website at http://www.alliedmarketresearch.com/intravenous-immunoglobulin-IVIG-market

Intravenous immunoglobulin (IVIG) is the parenteral preparation of purified immunoglobulin derived from large pools of human plasma containing antibodies against a broad spectrum of bacterial and viral agents. The IVIG demand has been growing on account of increased usage in primary immunodeficiency and application in newer indications. The emerging concept of hyper-immune globulin is likely to increase the efficacy of IVIG treatments by providing passive immunity to patients against disease causing agents. Allied Market Research estimates that about 130 tons of IVIG was issued in 2014 and is expected to reach 215 tons by 2021.

On contrary, the side effects associated with the use of IVIG infusion would restrict the market growth to an extent. Moreover, current high cost of IVGI treatment may trigger a shift towards cost effective corticosteroids treatment, restraining the IVIG market growth. However, improved production and purification techniques along with the improved plasma yield would help to overcome cost constraints; eventually supplementing the growth of IVIG market. Furthermore, anticipated approval for Alzheimer's and Multiple Sclerosis provides growth opportunity for the IVIG market.  

Similar market studies by Allied Market Research -

Global Biosimilars/Follow-on-Biologics Market - Biosimilars or follow-on-biologics are the "copied" version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.

View the global biosimilars/follow-on-biologics market report at http://www.alliedmarketresearch.com/biosimilars-market

Global Oncology/Cancer Drugs Market - Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.

View the global oncology/cancer drugs market report at http://www.alliedmarketresearch.com/oncology-cancer-drugs-market

Key finding of the study: 

• Chronic inflammatory demyelinating polyneuropathy (CIDP) and the hypogammaglobulinemia are the leading application for IVIG, collectively contributing about 2/5^th of the market revenue
• Congenital AIDS is projected to be one of the fastest-growing application segments at a CAGR 9.3% during the forecast period
• North America will remain the leading region throughout the forecast period, 2015-2021, closely followed by the Asia-Pacific
• Europe is projected to be the fastest growing IVIG market during 2015-2021

Geographically, North America and Asia-Pacific constitute the two largest markets for IVIG, collectively accounted for ~75% of the market revenue in 2014. Higher adoption rates, large patient population, and the presence of largest plasma collection & manufacturing base are the key factors responsible for the growth of IVIG market in these regions. However, the market growth outlook across developing economies is also looking strong, owing to increasing awareness towards immunodeficiency and rare autoimmune diseases, favorable reimbursement initiatives and improved healthcare expenditure.

Grifols S.A., CSL Behring, and Baxter International are identified as top three market players in 2014. Other key IVIG manufacturing companies profiled in the report Baxter international Inc., CSL Behring, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.

About Us: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based inPortland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Direct: +1(503)505-6949
Toll Free: +1(855)711-1555 (U.S. & Canada)
Fax: +1(855)550-5975
E-mail: sales@alliedmarketresearch.com

SOURCE Allied Market Research